Research
Hormonal
CJC-1295 and Ipamorelin restore youthful growth hormone secretion patterns by preserving physiological pulsatility, avoiding the adverse effects of continuous exogenous GH administration.
CJC-1295 and Ipamorelin are peptides that stimulate natural growth hormone pulses, potentially reversing age-related muscle loss and fat gain. While they show promise in restoring youthful GH patterns, they are not FDA-approved for anti-aging, and long-term safety data is lacking.
ModerateSupportsMEDIUM confidence
Unlike exogenous GH administration that suppresses endogenous production and eliminates pulsatility, CJC-1295 preserves physiological pulsatile GH release while increasing both pulse amplitude and trough levels... Ipamorelin complements CJC-1295 by stimulating GH release through ghrelin receptor activation... potent GH release without cortisol or prolactin elevation.
Why this rating
Supported by Phase 2 trials and animal studies, but commercial development ceased and long-term safety is unknown.
Source
Therapeutic peptides in gerontology: mechanisms and applications for healthy aging
Volodymyr Mavrych et al. · Frontiers in Aging · 2026
DOI 10.3389/fragi.2026.1790247
narrative_review
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Tirzepatide, a dual GIP/GLP-1 receptor agonist, significantly improves metabolic parameters associated with biological aging by restoring glycemic control and reducing visceral adiposity.Strong
- Epitalon, a tetrapeptide, extends cellular lifespan by activating telomerase and lengthening telomeres, while also modulating pineal gland function to restore melatonin synthesis.Limited
- BPC-157 and TB-500 enhance tissue repair and angiogenesis in aged tissues, showing promise in small pilot studies for chronic pain and wound healing.Limited
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →